Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Paclitaxel
Related studies linked through entity extraction aliases.
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of INCB123667 in Subjects With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
SMMART Adaptive Clinical Treatment (ACT) Trial
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
- Status
- WITHDRAWN
- Phase
- PHASE2
Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer
- Status
- UNKNOWN
- Phase
- NA
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
- Status
- RECRUITING
- Phase
- PHASE4
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1